1 / 43

An Approach to Fever Without an Apparent Source In the Pneumococcal Conjugate Vaccine Era

An Approach to Fever Without an Apparent Source In the Pneumococcal Conjugate Vaccine Era. R. Dagan The Pediatric Infectious Disease Unit Soroka University Medical Center Ben-Gurion University Beer-Sheva, Israel. Fever Without Apparent Source. Statement of the problem

desma
Télécharger la présentation

An Approach to Fever Without an Apparent Source In the Pneumococcal Conjugate Vaccine Era

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. An Approach to Fever Without an Apparent Source In the Pneumococcal Conjugate Vaccine Era R. Dagan The Pediatric Infectious Disease Unit Soroka University Medical Center Ben-Gurion University Beer-Sheva, Israel

  2. Fever Without Apparent Source • Statement of the problem • Status before and after Hib vaccination • Pneumococcal conjugate vaccine (PCV) • Will we modify our approach after introduction of PCV?

  3. Fever Without Apparent Source • Statement of the problem • Status before Hib vaccination • Pneumococcal conjugate vaccine (PCV) • Will we modify our approach after introduction of PCV?

  4. Fever The single most common chief complaint made to physicians who evaluate ambulatory children 30% of outpatient visits to clinic 20% of ER encounters (USA)

  5. Febrile Episodes are Usually • Short-lived • Responsive to antipyretics • Uneventful • Subside without specific Rx Most children presenting with fever are <2 years of age

  6. Possibility of occult bacteremia

  7. Outcome of Febrile Infants Aged 3-24 m with Occult Bacteremia 1 2 3 CURE FOCAL SYSTEMIC + (mild to moderate) SERIOUS FOCAL OM bacteremia (sepsis) LRI meningitis skeletal skin + soft tissues etc.

  8. Sepsis  meningitis Possibility of occult bacteremia

  9. What is the Best Approach for Febrile Children Aged 3-24 mos Without Apparent Focus? • Follow up only • Blood culture alone • Blood culture and Rx • WBC; Blood culture only if >15,000/mm3; no Rx • WBC; Blood culture only if >15,000/mm3; Rx • Rx only

  10. Fever Without Apparent Source • Statement of the problem • Status before and after Hib vaccination • Pneumococcal conjugate vaccine (PCV) • Will we modify our approach after introduction of PCV?

  11. Occult Bacteremia in the Pre-Hib Vaccination Era • ~5% of highly febrile non-toxic appearing children aged 2-36 months without apparent focus had bacteremia • The risk for bacteremia •  with  WBC •  with  fever •  in males •  age 7-11 months

  12. WBC Blood Cx >15,000 /mm3 Antibiotics "classical" approach High fever No apparent focus Is this approach reasonable? • The risk for bacteremia •  with  WBC •  with  fever •  in males •  age 7-11 months

  13. Organism % of all cases S. pneumoniae 50-90% H. influenzae b 3-25% Others (Salmonella, N. meningitidis etc) < 5% S. pneumoniae: 1-4% H. influenzae b: 7-13% N. meningitidis: > 50% Occult Bacteremia in the Pre-Hib Vaccination Era • FEAR • Sepsis • Meningitis • Focal infections

  14. occult bacteremia: ~5% ~50 Bacteremia Meningitis 1 - 4% 7 - 13% > 50% 0 - 2 S. pneumoniae: 50-90% H. influenzae: 3-25% N. meningitidis: < 5% 25 - 45 0 - 2 1 - 13 1 - 2 1 - 2 Occult Bacteremia in the Pre-Hib Vaccination Era: What Is the Risk for Meningitis in Untreated Patients with Occult Bacteremia 1,000 children 3-36m high fever 1- 6/1,000 (0.1-0.6%)

  15. Introduction of Hib vaccines Universal vaccination Hib Invasive Cases In Israel 1989 - 2003

  16. occult bacteremia: ~5% ~50 Bacteremia Meningitis 1 - 4% 7 - 13% > 50% 0 - 2 S. pneumoniae: 50-90% H. influenzae: 3-25% N. meningitidis: < 5% 25 - 45 0 - 2 1 - 13 1 - 2 1 - 2 Occult Bacteremia in the Post-Hib Vaccination Era: What Is the Risk for Meningitis in Untreated Patients with Occult Bacteremia 1,000 children 3-36m high fever 1- 6/1,000 (0.1-0.6%)

  17. occult bacteremia: ~5% ~50 Bacteremia Meningitis 1 - 4% 7 - 13% > 50% 0 - 2 S. pneumoniae: 50-90% H. influenzae: 3-25% N. meningitidis: < 5% 25 - 45 0 - 2 1 - 13 1 - 2 1 - 2 Occult Bacteremia in the Post-Hib Vaccination Era: What Is the Risk for Meningitis in Untreated Patients with Occult Bacteremia 1,000 children 3-36m high fever 1- 6/1,000 (0.1-0.9%)

  18. occult bacteremia: ~4% ~40 Bacteremia Meningitis 1 - 4% 7 - 13% > 50% 0 - 2 S. pneumoniae: 50-90% H. influenzae: 3-25% N. meningitidis: < 5% 25 - 45 0 - 2 1 - 13 1 - 2 1 - 2 1- 4/1,000 (0.1-0.4%) Occult Bacteremia in the Post-Hib Vaccination Era: What Is the Risk for Meningitis in Untreated Patients with Occult Bacteremia 1,000 children 3-36m high fever

  19. Fever Without Apparent Source • Statement of the problem • Status before and after Hib vaccination • Pneumococcal conjugate vaccine (PCV) • Will we modify our approach after introduction of PCV?

  20. PCV7 2003 vs baseline  77% (<1 yr)  83% (1 yr)  64% (2 yr) Effect in Target Age Group Invasive Pneumococcal Disease Rates in Children < 3 Years, ABCs, 1998-2003 1 yr <1 yr 2 yrs 2003 data are preliminary Farely et al, ICP, Cancun, Mexico, August 2003

  21. 2003 vs baseline  77% (<1 yr)  83% (1 yr)  64% (2 yr) Effect in Target Age Group Invasive Pneumococcal Disease Rates in Children < 3 Years, ABCs, 1998-2003 ~  80% in invasive pneumococcal disease in children < 3 yrs 2003 data are preliminary Farely et al, ICP, Cancun, Mexico, August 2003

  22. Bacteremia Meningitis 1 - 4% 7 - 13% > 50% 0 - 2 S. pneumoniae: 50-90% H. influenzae: 3-25% N. meningitidis: < 5% 25 - 45 0 - 2 1 - 13 1 - 2 1 - 2 Occult Bacteremia in the Post-Hib + PCV Vaccination Era: What Is the Risk for Meningitis in Untreated Patients with Occult Bacteremia IF Pnc Vaccine is PERFECT 1,000 children 3-36m high fever occult bacteremia: ~4% ~40 1- 4/1,000 (0.1-0.4%)

  23. occult bacteremia: ~1 ~10 Bacteremia Meningitis 1 - 4% 7 - 13% > 50% 0 - 2 S. pneumoniae: 50-90% H. influenzae: 3-25% N. meningitidis: < 5% 25 - 45 0 - 2 1 - 13 1 - 2 1 - 2 1- 2/1,000 (0.1-0.2%) Occult Bacteremia in the Post-Hib + PCV Vaccination Era: What Is the Risk for Meningitis in Untreated Patients with Occult Bacteremia IF Pnc Vaccine is PERFECT 1,000 children 2-36m high fever

  24. How Many Children Aged 2-36 m with High Fever Do We Have to Treat to Prevent Meningitis?* Simplistic calculation *assuming all meningitis cases present BRFORE the penetration of organisms to meninges

  25. How Many Children Aged 2-36 m with High Fever Do We Have to Treat to Prevent Meningitis?* Simplistic calculation In reality, antibiotic Rx reduces only by ~1/2 the risk for meningitis *assuming all meningitis cases present BRFORE the penetration of organisms to meninges

  26. How Many Children Aged 2-36 m with High Fever Do We Have to Treat to Prevent Meningitis?* Simplistic calculation PERIOD Pre-Hib Vaccine Post-Hib vaccine Post-PCV Expected cases of meningitis 1 - 6 1 - 4 1 - 2 Number of cases treated to prevent 1 case of meningitis 334 - 1,998 500 - 1,998 1,000 - 1,998 *assuming all meningitis cases present BRFORE the penetration of organisms to meninges

  27. Incidence of Occult Bacteremia Among Highly Febrile Young Children in the Era of the PCV A Study From a Children’s Hospital Emergency Department and Urgent Care Center Stoll & Rubin Arch Pediatr Adolesc Med 158:671-5, 2004

  28. Comparison of Data Post Hib Vaccination, Pre and Post PCV Stoll & Rubin Arch Pediatr Adolesc Med 158:671-5, 2004

  29. Comparison of Data Post Hib Vaccination, Pre and Post PCV Stoll & Rubin Arch Pediatr Adolesc Med 158:671-5, 2004

  30. Comparison of Data Post Hib Vaccination, Pre and Post PCV Stoll & Rubin Arch Pediatr Adolesc Med 158:671-5, 2004

  31. Rate Difference (Observed–Expected) of Pneumococcal–Related Diseases per 1000 Children Aged Younger than 2 Years 2nd Year After Vaccine Introduction Tenn NY Tenn NY Tenn NY Rate difference / 1000 children < 2yrs in 2001-2 Pneumonia + invasive infections AOM Other ARIs * statistically significant Poehling al, Pediatr, 114:755–761, 2004

  32. After Introduction of PCV, Compared with the Pre-PCV Era, We Expect to See: •  of visits due to fever with no focus • Of those with fever without focus,  % with bacteremia • However, same risk for bacteremia as before if >390C & >20,000 WBCs For a child with >390C + WBC and > 20,000/mm3, PCV will not decrease significantly the risk for bacteremia

  33. < 24 m (n = 178) Invasive Pnc Isolate - Israel 1998-2001 7-valent vaccine serotypes 24-47 m (n = 59)

  34. Replacement phenomenon

  35. Invasive Pneumococcal Disease in Atlanta 2 mo - 4 yrs 1997-9 vs. 2001-3 2003 data are preliminary Farely et al, ICP, Cancun, Mexico, August 2003

  36. Fever Without Apparent Source • Statement of the problem • Status before and after Hib vaccination • Pneumococcal conjugate vaccine (PCV) • Will we modify our approach after introduction of PCV?

  37. After Introduction of PCV, Compared with the Pre-PCV Era, We Expect to See: •  of visits due to fever with no focus • Of those with fever without focus,  % with bacteremia • However, same risk for bacteremia as before if >390C & >20,000 WBCs For a child with >390C + WBC and > 20,000/mm3, PCV will not decrease significantly the risk for bacteremia

  38. No •  risk for bacteremia •  WBC •  fever • male • age 7-11 mos ? "ill" , "toxic", "lethargic" etc.... Yes >20,000 WBC/mm3 ? ? ? Yes Consider Yes Antibiotic Rx AMOX or specify why other How Should a Highly Febrile Child Aged 2-36 mos Without Apparent Focus Be Managed at the ER? • Age 2-36 mos • Temp. > 390C Regardless of PCV status

  39. The consensus is that there is no consensus

  40. For every complex problem there is a simple solution....... which is false

  41. How Many Children Aged 2-36 m with High Fever Do We Have to Treat to Prevent Meningitis? • The simplistic calculation assumes that: • Risk is equal for all WBC counts • Risk is equal for allTemp. • Risk is equal for allages • Risk is equal for both sexes • Risk is equal for well vs ill appearing • Treatment prevents all cases of meningitis • PCV will prevent all S. pneumoniae cases

  42. How Many Children Aged 2-36 m with High Fever Do We Have to Treat to Prevent Meningitis? • The simplistic calculation assumes that: • Risk is equal for all WBC counts ( WBC >  WBC) • Risk is equal for allTemp. ( Temp. >  Temp.) • Risk is equal for allages ( 6-11 months) • Risk is equal for both sexes (M > F) • Risk is equal for well vs ill appearing (ill > well) • Treatment prevents all meningitis cases (only 1/2 -1/3) • PCV will prevent all S. pneumoniae cases (incorrect)

More Related